שווי פעילות לרווח לפני ריבית, מסים ופחת Kineta (KA)

The EV/EBITDA valuation chart for Kineta, Inc. (KA) demonstrates the development of a business striving to expand its KVA12123 antibody portfolio through B2B deals. The current metric stands at , however, pricing power has been lost due to a capital shortage, which led to a halt in research. Despite the crisis, Kineta, Inc. maintains its status as an immuno-oncology innovator, relying on the value of its patents for combating resistant tumors.

The high potential for pricing power of Kineta, Inc. (KA) in immuno-oncology, driven by the uniqueness of the KVA12.1 antibody, necessitates a precise business valuation. The EV/EBITDA multiple, accounting for capital structure, compares the total enterprise value of the company, including net debt, with its operating profit before interest, taxes, depreciation, and amortization. This chart allows investors to determine the real value of assets by eliminating distortions caused by the issuer's tax burden and debt strategy.